GlassScriptPhysician profile
Viktoria Vida Loydall
NPI 1194080226
$1,719.98
in general payments reported to CMS, 2019-2025
16 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $173 · 2021: $81.27 · 2022: $414 · 2023: $314 · 2024: $287 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752 · Entertainment: $99.59 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.25 |
| Entertainment | $99.59 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $617.35 | 2019-2025 | Precision 1, Dailies Total1, Total30 |
| Sun Pharmaceutical Industries INC. | $245.01 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $146.15 | 2023-2024 | Infuse, Miebo |
| Glaukos Corporation | $117.19 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $108.63 | 2019-2021 | |
| Optos, INC. | $99.59 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $99.16 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $62.85 | 2024 | |
| Sight Sciences, INC. | $54.69 | 2022 | |
| Coopervision INC. | $36.66 | 2023-2024 | Myday Contact Lens, Misight Contact Lens |
| Kala Pharmaceuticals, INC. | $30.52 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $24.59 | 2019 | |
| Allergan, INC. | $23.13 | 2021 | |
| Biotissue Holdings INC. | $20.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.45 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $15.24 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viktoria Loydall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.